Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al
Its varied potential mechanisms are thought to include interaction with inducible and/or endothelial nitric oxide-generating systems, by influencing serotonin, dopamine, GABA, and/or opioid metabolism, and/or by directly aiding blood flow, repair, regrowth, angiogenesis, and remodeling
Methods: A comprehensive synthesis of preclinical and clinical studies was conducted, focusing on the cellular mechanisms and systemic outcomes of GLP-1RA therapy in various models of sepsis and critical illness
Patients in the dataset had a 2.56 times higher rate of developing NAION within 1 year after starting a GLP-1 receptor agonist than those in the dataset who started a dipeptidyl peptidase-4 (DPP-4) inhibitor
The body can make it, but demand may rise during illness, injury, intense training or other metabolic stress
Archived from the original (PDF) on 10 March 2014